Menu

Report Library

All Reports

Biomedtracker Q2 2017 Outlook Report

March 31, 2017

In this report, we cover catalysts from 23 drugs expected to occur in Q2 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Early 2017 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q2 2017.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.


Meddevicetracker Q2 2017 Outlook Report

Separately, Biomedtracker’s sister product, Meddevicetracker has published a concurrent report on 14 device catalysts expected to occur in Q2 2017. This report can be downloaded for free here.

For more information on Meddevicetracker, visit its website www.meddevicetracker.com.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Alzheimer's Disease (AD)
Bladder Cancer
Clostridium difficile-Associated Diarrhea/Infection (CDAD/CDI)
Glaucoma / Ocular Hypertension (Ophthalmology)
Hemophilia B
Hereditary Angioedema (HAE)
HIV / AIDS Treatment
Migraine and Other Headaches
Multiple Sclerosis (MS)
Muscular Dystrophy - Unspecified
Ovarian Cancer
Pancreatic Cancer
Parkinson's Disease (PD)
Postsurgical Pain
Seizure Disorders (Epilepsy)
Skin and Skin-Structure Infections (Antibacterial)
Uterine (Endometrial) Cancer
Uveitis (Ophthalmology)
Vaginal Atrophy
Venous Thromboembolism (VTE)
X-Linked Hypophosphatemia (XLH)

 Additional Resources: